| Indicators | Browse All

Surrozen, Inc. (SRZN)

Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
23.39 USD +0.02 (0.086%) ⇧ (June 12, 2026, 4 p.m. EDT)
After hours: 23.39

Short-term:★★⯪☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | June 7, 2026, 5:46 a.m. EDT

The immediate outlook is neutral-to-slightly-bearish as the stock trades at a discount to its moving averages, yet the overwhelming long-term picture is a severe value trap driven by a catastrophic multi-year decline. While the balance sheet currently shows a fortress-like liquidity position with massive cash reserves relative to debt, the business fundamentals are deteriorating rapidly, evidenced by negative operating margins, significant free cash flow burn, and a trailing twelve-month loss that renders the forward P/E meaningless. The price history confirms this structural failure, showing a nearly 94% drop over the last four years with the most recent annual performance also in the red. Although recent insider option grants and a 5.9% intraday surge suggest temporary speculative interest, these do not offset the reality that the company is burning cash without sustainable profitability. With no dividend history to speak of, investors are left with a high-risk biotech play that lacks the revenue growth or margin expansion required to justify its current valuation.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL_79 ✓0.083464
MSTL0.089038
AutoETS0.089307
AutoARIMA0.089308
AutoTheta0.100133
MSTL_79_1050.102113
MSTL_1050.129392

Forecast horizon: 60 days | Selected: MSTL_79

Forecast Reliability
Score 33%
H-stat 2.32
Ljung-Box p 0.000
Jarque-Bera p 0.442
Excess Kurtosis -0.14
Attribute Value
Sector Healthcare
Revenue per Share 0.805
Market Cap 271,566,560
Forward P/E -5.87
Beta 0.51
Previous Name Consonance-HFW Acquisition Corp.
Website https://www.surrozen.com

Info Dump

Attribute Value
52 Week Change 1.451782
Address1 171 Oyster Point Boulevard
Address2 Suite 400
All Time High 210.0
All Time Low 4.5
Ask 29.69
Ask Size 2
Average Daily Volume10 Day 90,100
Average Daily Volume3 Month 103,211
Average Volume 103,211
Average Volume10Days 90,100
Beta 0.506
Bid 17.14
Bid Size 2
Book Value -24.208
City South San Francisco
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 23.39
Current Ratio 11.913
Custom Price Alert Confidence HIGH
Date Short Interest 1,780,012,800
Day High 25.13
Day Low 23.0001
Display Name Surrozen
Earnings Timestamp End 1,746,821,116
Earnings Timestamp Start 1,746,821,116
Ebitda -42,689,000
Ebitda Margins 0.0
Enterprise To Ebitda -4.016
Enterprise To Revenue 22.876
Enterprise Value 171,434,576
Eps Current Year -3.7
Eps Forward -3.985
Eps Trailing Twelve Months -36.59
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 28.1418
Fifty Day Average Change -4.7518005
Fifty Day Average Change Percent -0.16885205
Fifty Two Week Change Percent 145.17819
Fifty Two Week High 35.0
Fifty Two Week High Change -11.610001
Fifty Two Week High Change Percent -0.3317143
Fifty Two Week Low 8.0
Fifty Two Week Low Change 15.389999
Fifty Two Week Low Change Percent 1.9237499
Fifty Two Week Range 8.0 - 35.0
Financial Currency USD
First Trade Date Milliseconds 1,610,375,400,000
Float Shares 4,752,821
Forward Eps -3.985
Forward P E -5.8695107
Free Cashflow -26,107,124
Full Exchange Name NasdaqCM
Full Time Employees 44
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -24,641,000
Has Pre Post Market Data 1
Held Percent Insiders 0.03176
Held Percent Institutions 1.01878
Implied Shares Outstanding 11,610,371
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-08-12
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,702,512,000
Last Split Factor 1:15
Long Business Summary Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Long Name Surrozen, Inc.
Market us_market
Market Cap 271,566,560
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_401948183
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-06-12
Net Income To Common -342,560,992
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 271,392,422
Number Of Analyst Opinions 4
Open 23.67
Operating Cashflow -33,460,000
Operating Margins -2.0911999
Payout Ratio 0.0
Phone 650 489 9000
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 23.39
Post Market Time 1,781,294,410
Prev Name Consonance-HFW Acquisition Corp.
Previous Close 23.37
Price Eps Current Year -6.3216214
Price Hint 2
Price To Book -0.9662095
Price To Sales Trailing12 Months 36.237865
Profit Margins 0.0
Quick Ratio 11.7
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0199986
Regular Market Change Percent 0.0855736
Regular Market Day High 25.13
Regular Market Day Low 23.0001
Regular Market Day Range 23.0001 - 25.13
Regular Market Open 23.67
Regular Market Previous Close 23.37
Regular Market Price 23.39
Regular Market Time 1,781,294,400
Regular Market Volume 71,099
Return On Assets -0.22819
Revenue Growth 4.086
Revenue Per Share 0.805
Sand P52 Week Change 0.23177934
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 11,610,371
Shares Percent Shares Out 0.0475
Shares Short 551,841
Shares Short Previous Month Date 1,777,507,200
Shares Short Prior Month 565,307
Short Name Surrozen, Inc.
Short Percent Of Float 0.0864
Short Ratio 5.82
Source Interval 15
State CA
Symbol SRZN
Target High Price 44.0
Target Low Price 40.0
Target Mean Price 42.5
Target Median Price 43.0
Total Cash 106,910,000
Total Cash Per Share 9.208
Total Debt 6,778,000
Total Revenue 7,494,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -36.59
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 21.09443
Two Hundred Day Average Change 2.2955685
Two Hundred Day Average Change Percent 0.10882343
Type Disp Equity
Volume 71,099
Website https://www.surrozen.com
Zip 94,080